Azenta Life Sciences

The adeno-associated virus (AAV) is a powerful vehicle for cell or gene therapy; however, working with AAV vectors can be challenging. Each construct contains two inverted terminal repeat (ITR) sequences which are notoriously unstable, but also critical to replication and encapsidation of viral DNA.  To support AAV-based research and therapeutic applications, the GENEWIZ genomics team from Azenta Life Sciences developed an AAV packaging workflow centered around its proprietary AAV plasmid synthesis process for industry-leading project quality, completion time, and flexibility to deliver results for any AAV challenge.

Learn More

With conventional methods, only important regions of plasmids are sequenced which can fail to detect unwanted changes in other areas during replication and leave you to piece together an entire plasmid map. Using long-read sequencing, Plasmid-EZ provides complete verification of plasmid integrity and fidelity with results delivered in as fast as 1 business day.Now connected to our expansive dropbox network, Plasmid-EZ offers unparalleled convenience for sample submission. Simply order directly through our customer portal and deposit your samples at one of our convenient dropboxes.

Learn More

Biomarker identification has served as a bedrock to accelerate all aspects of drug discovery, from preclinical research, through clinical development and enabling approval by regulatory agencies. The development of novel strategies for mid- to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, Azenta Life Sciences, formerly GENEWIZ, has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts.​ In this tech note, discover the science behind this assay and how its optimal approach makes it easier to incorporate protein biomarker discovery into your preclinical and clinical research.

Learn More

A critical portion of every cell or gene therapy study is the long-term follow-up (LTFU) observations to monitor the safety of therapeutic products.  Regulatory guidance for LTFU focuses on integration site analysis (ISA) as a method to identify the location and frequency of vector integration.  Azenta Life Sciences, formerly GENEWIZ, partners with you by implementing our pre-optimized ISA protocols through pre-clinical and clinical sample collection and management over the course of your trial.  The result is total confidence in your study data working with a single, experienced clinical trial partner.

Learn More

Understand AAV workflows through detailed lab and bioinformatic processes!

Adeno-associated virus (AAV) vectors have become an ideal vehicle for in vivo gene therapy due to their efficiency and safety in humans. However, there are many challenges to overcome during the AAV production process for rapid drug development.

Led by Andrea O'Hara, Ph.D., this workshop will help you understand the AAV workflow by covering AAV lab and bioinformatics analysis processes. Starting with upstream development, we review the gene synthesis, AAV plasmid preparation, and sequencing options available for AAV production and validation. We then discuss downstream analysis of the final packaged product to confirm purity, clonality, and fidelity.

Learn More